Navigation Links
PharmaVentures Helps Secure Investor for Former MSD Research Site
Date:1/19/2012

OXFORD, England, January 19, 2012 /PRNewswire/ --

PharmaVentures announced today that it was delighted to act as transaction advisor to MSD (operating in the US and Canada as Merck & Co) to secure its deal with BioCity Scotland, a new joint venture between BioCity Nottingham and Roslin BioCentre, for the former MSD research facility in Newhouse, Lanarkshire.

The deal follows exceptional collaborative working between MSD, the Scottish Life Sciences community and the Scottish Government.

The transfer of this research facility from MSD to BioCity Scotland unlocks over 130,000 sq ft of purpose-built laboratories and offices on the 23 acre site capable of supporting drug discovery and development for growing bioscience, pharmaceutical, med-tech and healthcare companies.  

Fintan Walton, Chief Executive of PharmaVentures, said: "PharmaVentures is delighted to have worked with MSD in finding a new investor like BioCity Scotland to turn the former MSD research facility into an incubator for growing innovative enterprises. This is a fantastic outcome for the site and for the UK Life Science industry as a whole, creating new job opportunities from start-up companies and providing the infrastructure to support expansion of existing businesses."

Note to Editors

If you wish to write an article, please contact us for any further information you require.

About PharmaVentures:

PharmaVentures (http://www.pharmaventures.com) is an international healthcare advisory group providing leadership in all aspects of deals and alliances, from strategy formulations to implementation. The company occupies a special position in the global marketplace because of their track record of successful outcomes, resulting from their unique insight into the world of deal making, their internationally recognised analytical and valuation capabilities, their own proprietary deal making database PharmaDeals®  (http://www.pharmadeals.net), containing over 42,000 deal records, and their extensive business relationship network and our outstanding success in M&A transactions.

Over the years PharmaVentures has built considerable experience in the M&A field including the divestment of manufacturing and R&D businesses most of which have led to both the protection and the creation of jobs.

Their services cover:

  • Valuation (for licensing, acquisitions, divestments, fund raising & expert testimonies)
  • Licensing (in and out-licensing)
  • M&A (companies & assets)
  • Strategy (commercialisation, deal strategy, due diligence, market entry)
  • Expert Testimony (patent infringement, deal disagreements, taxation, determining damages)

Now in its 20th year, PharmaVentures is based in Oxford, UK, and employs over 30 people.

PharmaDeals® and PharmaVentures® are registered Trade Marks of PharmaVentures Ltd.

For further information, contact:

Dr Fintan Walton, Chief Executive, PharmaVentures
+44(0)1865-332-700
fintan.walton@pharmaventures.com



'/>"/>
SOURCE PharmaVentures
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. PharmaVentures Client Sanofi Wins Scrip Outsourcing Deal of the Year Award
2. PharmaVentures Appoints Andy Smith as Head of Corporate Finance
3. PharmaVentures Engaged by Astex Therapeutics to Assist in the Divestment of US Facility
4. Matrix Corporate Capital and PharmaVentures Announce the Signing of a Memorandum of Understanding (MOU)
5. PharmaVentures Corporate Advisory Appoints Nikki Watkins as Practice Head, Product & Portfolio Strategy
6. PharmaVentures Assists Helsinn in the Successful Sale of Helsinn Chemicals Ireland to the Medinco C.F.M. Group
7. Merck Engages PharmaVentures to Assist in the Divestment of its Italian Research Centre IRBM
8. Software Helps Research Facilities Meet New NIH Financial Conflict of Interest (FCOI) Requirements
9. FindTheBest Helps Parents Find Cord Blood Banks
10. Mirage-effect helps researchers hide objects
11. The Vitality Group Helps U.S. Businesses Navigate New Legal Environment for Health and Wellness Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building and ... rebranding initiative announced today. The bold new look is part of a transformation ... moves into a significant growth period. , It will also expand its service offering ...
(Date:10/10/2017)... , Oct. 10, 2017 International research firm Parks Associates ... will speak at the TMA 2017 Annual Meeting , October 11 ... in the residential home security market and how smart safety and security ... Parks Associates: ... "The residential security ...
(Date:10/9/2017)... 9, 2017  BioTech Holdings announced today identification ... its ProCell stem cell therapy prevents limb loss ... Company, demonstrated that treatment with ProCell resulted in ... as compared to standard bone marrow stem cell ... in reduction of therapeutic effect.  ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... journal, Epilepsia, Brain Sentinel’s SPEAC® System which uses the surface electromyography (sEMG) ... tonic-clonic seizures (GTCS) using surface electromyography (sEMG). The prospective multicenter phase III ...
Breaking Biology Technology:
(Date:3/30/2017)... , March 30, 2017 The research ... system for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D ... a new realm of speed and accuracy for use in identification, ... an affordable cost. ... ...
(Date:3/28/2017)... March 28, 2017 The report ... (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), ... - Global Forecast to 2022", published by MarketsandMarkets, the ... and is projected to reach USD 75.64 Billion by ... 2022. The base year considered for the study is ...
(Date:3/24/2017)... 2017 Research and Markets has announced the ... & Trends - Industry Forecast to 2025" report to their ... The Global ... CAGR of around 15.1% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
Breaking Biology News(10 mins):